To study the effect of infusion of stem cells derived from own bone marrow into the ovaries in cases of early onset of depletion of ovarian follicles

Conditions

Health Condition 1: O090- Supervision of pregnancy with history of infertility

Namit Kant Singh, Garima Patel, Y Dogra, Sriloy Mohanty, T. Seth

Human Reproduction2022-06-291 citations

P–796 Trial of Autologous Marrow derived Stem Cell Ovarian Transplantation (TAMSCOT) in young infertile women with diminished ovarian reserve for ovarian rejuvenation – HOPE still persists

Neha Singh, Yogita Dogra, Sriloy Mohanty, T. Seth

Human Reproduction2021-07-011 citations

10.1093/humrep/deab130.795

P-796 Trial of Autologous Marrow derived Stem Cell Ovarian Transplantation (TAMSCOT) in young infertile women with diminished ovarian reserve for ovarian rejuvenation – HOPE still persists

Nilanchali Singh, Yogita Dogra, Sriloy Mohanty, T. Seth

Human Reproduction2021-07-011 citations

10.1093/humrep/deab128.037

Interventions

Intervention1: Bone Marrow derived Stem Cells: 30 ml bone marrow aspirated and mononuclear cells will be isolated and tagged with antobody followed by flow cytometry assessment of the cells.2ml stem c

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 20-38 years 2. Normal karyotype 3. Adequate uterine cavity either by imaging or hysteroscopically 4. Normal thyroid function tests 5. Diagnosis of premature ovarian failure by FSH > 25IU/l, and/or primary or secondary amenorrhea at least for 4 months 6. Diminished ovarian reserve - AFC 8 IU/l) 7. No other cause of female infertility 8. Normal autoimmune work up â?? anti TPO, FBS(R/O IDDM),Complete blood count (R/O ITP, Hemolytic anemia), Anti nuclear antibodies (R/O SLE)

Exclusion criteria

Exclusion criteria: 1. Past or present evidence of gynecological malignancy 2. Type 1 or II Diabetes Mellitus 3. Presence of anemia ( Hb 4. Contraindications of bone marrow harvesting as per departmental protocol 5. Acquired poor ovarian reserve (Chemotherapy, radiotherapy) 6. Ovarian endometriosis 7. Prior ovarian surgery

Design outcomes

Primary

Measure	Time frame
a. Improved diagnostic hormonal levels ( FSH , AMH , Estradiol) b. Improved USG parameters- increase in AFC Timepoint: 1, 3 and 6 months after stem cell infusion	—

Secondary

Measure	Time frame
a. Spontaneous or after Controlled ovarian hyperstimulation (COH) : Biochemical Pregnancy Rate â?? Defined as serum Î²-hCG value of more than 100IU detected 16 days after embryo transfer. b. Spontaneous or after COH: Clinical pregnancy rate â?? Defined as evidence of pregnancy by visualization of intrauterine gestation sac and embryonic pole with heartbeat on ultrasound performed 6 weeks after embryo transfer . Timepoint: a. 16 days after embryo transfer b. 6 weeks if pregnancy	—

Measure

Time frame

a. Spontaneous or after Controlled ovarian hyperstimulation (COH) : Biochemical Pregnancy Rate â?? Defined as serum Î²-hCG value of more than 100IU detected 16 days after embryo transfer. b. Spontaneous or after COH: Clinical pregnancy rate â?? Defined as evidence of pregnancy by visualization of intrauterine gestation sac and embryonic pole with heartbeat on ultrasound performed 6 weeks after embryo transfer . Timepoint: a. 16 days after embryo transfer b. 6 weeks if pregnancy

—

Countries

India

Contacts

Public ContactYogita Dogra

All India Institute of Medical Sciences

dryogitadogra@gmail.com7018955300

Outcome results

None listed